File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children: A randomized controlled trial

TitleSafety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children: A randomized controlled trial
Authors
Issue Date1996
PublisherAmerican Medical Association. The Journal's web site is located at http://jama.ama-assn.org/index.dtl
Citation
Journal Of The American Medical Association, 1996, v. 275 n. 19, p. 1499-1503 How to Cite?
AbstractObjective. - To assess the safety and immunogenicity of a bivalent serogroups A/C meningococcal oligosaccharide-protein conjugate vaccine compared with the licensed meningococcal polysaccharide vaccine. Design. - Randomized controlled trial. Study population. - Ninety healthy 18- to 24- month-old children who were seen at a southern California Kaiser Permanente clinic. Interventions. - Vaccination with either the meningococcal conjugate vaccine (at 1 of 2 dosages) or the polysaccharide vaccine, with 2 doses given 2 months apart. Main Outcome Measures. - Immune response to each vaccine dose as determined by measurement of serogroup-specific total antibodies by enzyme-linked immunosorbent assay (ELISA) and by assessment of serum bactericidal activity. Results. - Both vaccines appeared to be safe, and nearly all children responded with greater than 4-fold increases in antibody levels. The 2 dosages of the conjugate vaccine induced similar antibody responses; therefore, the data for the 2 conjugate vaccine groups were combined. Following 2 doses. ELISA antibody levels against group C meningococcus were significantly higher in conjugate vaccine recipients than in polysaccharide vaccine recipients (16.66 μg/mL vs 8.31 μg/mL; P<.001), but antibody levels against group A were not significantly different (22.75 μg/mL vs 21.24 μg/mL; P=.70). The serum bactericidal assays showed striking differences between the conjugate and polysaccharide vaccine groups. Geometric mean serum bactericidal titers were significantly higher in conjugate vaccine recipients (755.6 vs 37.6 for group A, P<.001; 3197.9 vs 11.4 for group C, P<.001). Conclusions. - The immune response induced by this meningococcal oligosaccharide-protein conjugate vaccine was qualitatively different from that induced by the polysaccharide vaccine, and the antibodies it elicited provided greater functional activity.
Persistent Identifierhttp://hdl.handle.net/10722/79982
ISSN
2015 Impact Factor: 37.684
2015 SCImago Journal Rankings: 6.440
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLieberman, JMen_HK
dc.contributor.authorChiu, SSen_HK
dc.contributor.authorWong, VKen_HK
dc.contributor.authorPartridge, Sen_HK
dc.contributor.authorChang, SJen_HK
dc.contributor.authorChiu, CYen_HK
dc.contributor.authorGheesling, LLen_HK
dc.contributor.authorCarlone, GMen_HK
dc.contributor.authorWard, JIen_HK
dc.date.accessioned2010-09-06T08:01:01Z-
dc.date.available2010-09-06T08:01:01Z-
dc.date.issued1996en_HK
dc.identifier.citationJournal Of The American Medical Association, 1996, v. 275 n. 19, p. 1499-1503en_HK
dc.identifier.issn0098-7484en_HK
dc.identifier.urihttp://hdl.handle.net/10722/79982-
dc.description.abstractObjective. - To assess the safety and immunogenicity of a bivalent serogroups A/C meningococcal oligosaccharide-protein conjugate vaccine compared with the licensed meningococcal polysaccharide vaccine. Design. - Randomized controlled trial. Study population. - Ninety healthy 18- to 24- month-old children who were seen at a southern California Kaiser Permanente clinic. Interventions. - Vaccination with either the meningococcal conjugate vaccine (at 1 of 2 dosages) or the polysaccharide vaccine, with 2 doses given 2 months apart. Main Outcome Measures. - Immune response to each vaccine dose as determined by measurement of serogroup-specific total antibodies by enzyme-linked immunosorbent assay (ELISA) and by assessment of serum bactericidal activity. Results. - Both vaccines appeared to be safe, and nearly all children responded with greater than 4-fold increases in antibody levels. The 2 dosages of the conjugate vaccine induced similar antibody responses; therefore, the data for the 2 conjugate vaccine groups were combined. Following 2 doses. ELISA antibody levels against group C meningococcus were significantly higher in conjugate vaccine recipients than in polysaccharide vaccine recipients (16.66 μg/mL vs 8.31 μg/mL; P<.001), but antibody levels against group A were not significantly different (22.75 μg/mL vs 21.24 μg/mL; P=.70). The serum bactericidal assays showed striking differences between the conjugate and polysaccharide vaccine groups. Geometric mean serum bactericidal titers were significantly higher in conjugate vaccine recipients (755.6 vs 37.6 for group A, P<.001; 3197.9 vs 11.4 for group C, P<.001). Conclusions. - The immune response induced by this meningococcal oligosaccharide-protein conjugate vaccine was qualitatively different from that induced by the polysaccharide vaccine, and the antibodies it elicited provided greater functional activity.en_HK
dc.languageengen_HK
dc.publisherAmerican Medical Association. The Journal's web site is located at http://jama.ama-assn.org/index.dtlen_HK
dc.relation.ispartofJournal of the American Medical Associationen_HK
dc.titleSafety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children: A randomized controlled trialen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0098-7484&volume=275; &issue=No 19&spage=1499&epage=1503&date=1996&atitle=Safety+and+Immunogenicity+of+a+Serogroups+A/C+Neisseria+meningitidis+Oligosaccharide+-+Protein+Conjugate+Vaccine+in+Young+Childrenen_HK
dc.identifier.emailChiu, SS:ssschiu@hkucc.hku.hken_HK
dc.identifier.authorityChiu, SS=rp00421en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1001/jama.275.19.1499en_HK
dc.identifier.pmid8622225-
dc.identifier.scopuseid_2-s2.0-0029875330en_HK
dc.identifier.hkuros22515en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0029875330&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume275en_HK
dc.identifier.issue19en_HK
dc.identifier.spage1499en_HK
dc.identifier.epage1503en_HK
dc.identifier.isiWOS:A1996UJ93700034-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLieberman, JM=7202237529en_HK
dc.identifier.scopusauthoridChiu, SS=7202291500en_HK
dc.identifier.scopusauthoridWong, VK=9734392200en_HK
dc.identifier.scopusauthoridPartridge, S=7006082311en_HK
dc.identifier.scopusauthoridChang, SJ=7405603722en_HK
dc.identifier.scopusauthoridChiu, CY=7402303939en_HK
dc.identifier.scopusauthoridGheesling, LL=6602984112en_HK
dc.identifier.scopusauthoridCarlone, GM=7004824268en_HK
dc.identifier.scopusauthoridWard, JI=7404120018en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats